The anti-proliferative and apoptotic effects of curcumin on feline mammary gland tumor cells in vitro

Document Type : Full paper (Original article)

Authors

1 Department of Medical Biology, Faculty of Medicine, Sakarya University, Sakarya, Turkey

2 Department of Obstetrics and Gynaecology, Faculty of Veterinary Medicine, Istanbul University-Cerrahpaşa, Istanbul, Turkey

3 MSc Student in Medical Biology, Department of Medical Biology, Institute of Health Science, Sakarya University, Sakarya, Turkey

4 Ph.D. Student in Biochemistry, Department of Medical Biochemistry, Institute of Health Science, Sakarya University, Sakarya, Turkey

5 Ph.D. Student in Gynecology, Department of Obstetrics and Gynecology, Faculty of Veterinary Medicine, Istanbul University-Cerrahpaşa, Istanbul, Turkey

6 Department of Pathology, Faculty of Veterinary Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey

10.22099/ijvr.2021.40452.5866

Abstract

Background: Feline mammary gland tumors (FMGTs) are the third most diagnosed tumors in cats. Feline mammary gland tumors have aggressive biological behavior and poor response to both surgical and medical treatments, thus, new therapeutic approaches are essential to improve. Curcumin (CUR) is a polyphenol component exhibiting anti-cancer effects and induces apoptosis through different mechanisms especially in human breast cancer. However, there is no study investigating the effects of CUR on FMGTs. Aims: The aim of this study was to determine the anti-proliferative and apoptotic effects of CUR on primary cell lines from FMGT tissue samples of two cases classified as carcinoma-simple, tubular type (grade III). Methods: The cytotoxic effect of CUR was determined by water-soluble tetrazolium salt-1 (WST-1) assay. Annexin V, cell cycle, and acridine orange (AO) analyses were performed to determine the apoptotic effect of CUR. Results: Our results showed that CUR had an anti-proliferative and apoptotic effect through induction of apoptosis and cell cycle arrest (G0/G1) on FMGT cells. Conclusion: Therefore, this is the first study that shows the effects of CUR on FMGTs. However, further molecular studies are required to compare the effects of CUR on different histopathological phenotypes and to determine the further molecular mechanisms including the potential apoptotic and cellular pathways affected by CUR.

Keywords

Main Subjects


Alkan, FU; Anlas, C; Cinar, S; Yildirim, F; Ustuner, O; Bakirel, T and Gurel, A (2014). Effects of curcumin in combination with cyclophosphamide on canine mammary tumor cell lines. Vet. Med. (Praha). 59: 553-572.
Banik, U; Parasuraman, S; Adhikary, AK and Othman, NH (2017). Curcumin: the spicy modulator of breast carcinogenesis. J. Exp. Clin. Cancer Res., 36: 98.
Calaf, GM; Ponce-Cusi, R and Carrión, F (2018). Curcumin and paclitaxel induce cell death in breast cancer cell lines. Oncol. Rep., 40: 2381-2388.
Cassali, GD; de Campos, CB; Bertagnolli, AC; Estrela-Lima, A; Lavalle, GE; Damasceno, KA; Di Nardi, AB; Cogliati, B; da Costa, FVA; Sobral, R; Di Santis, GW; Fernandes, CG; Ferreira, E; Salgado, BS; Vieira-Filho, CH da C; Silva, DN; Martins-Filho, EF; Teixeira, SV; Nunes, FC and Nakagaki, KYR (2018). Consensus for the diagnosis, prognosis and treatment of feline mammary tumors. Braz. J. Vet. Res. Anim. Sci., 55: e135084.
Chattopadhyay, I; Biswas, K; Bandyopadhyay, U and Banerjee, RK (2004). Turmeric and curcumin biological actions and medicinal applications. Curr. Sci., 87: 44-54.
Deguchi A (2015). Curcumin targets in inflammation and cancer. Endocr. Metab. Immune. Disord. Drug Targets., 15: 88-96.
Giménez, F; Hecht, S; Craig, LE and Legendre, AM (2010). Early detection, aggressive therapy: optimizing the management of feline mammary masses. J. Feline Med. Surg., 12: 214-224.
Giordano, A and Tommonaro, G (2019). Curcumin and Cancer. Nutrients. 11: 2376.
Goldschmidt, M; Pena, L; Rasotto, R and Zappulli, V (2011). Classification and grading of canine mammary tumors. Vet. Pathol., 48: 117-131.
Guan, F; Ding, Y; Zhang, Y; Zhou, Y; Li, M and Wang, C (2016). Curcumin suppresses proliferation and migration of MDA-MB-231 breast cancer cells through autophagy-dependent Akt degradation. PLoS One. 11: e0146553.
Guney Eskiler, G; Deveci Ozkan, A; Kaleli, S and Bilir, C (2019). Inhibition of TLR4/TRIF/IRF3 signaling pathway by curcumin in breast cancer cells. J. Pharm. Pharm. Sci., 22: 281-291.
Guney Eskiler, G; Sahin, E; Deveci Ozkan, A; Cilingir Kaya, OT and Kaleli, S (2020). Curcumin induces DNA damage by mediating homologous recombination mechanism in triple negative breast cancer. Nutr. Cancer. 72: 1057-1066.
Gupta, MK; Vadde, R and Sarojamma, V (2019). Curcumin - A novel therapeutic agent in the prevention of colorectal cancer. Curr. Drug Metab., 20: 977-987.
Hahni, KA and Adams, WH (1994). Feline mammary neoplasia: biological behaviour, diagnosis, and treatment alternatives. Feline Pract., 25: 5-11.
Ito, T; Kadosawa, T; Mochizuki, M; Matsunaga, S; Nishimura, R and Sasaki, N (1996). Prognosis of malignant mammary tumor in 53 cats. J. Vet. Med. Sci., 58: 723-726.
Komal, K; Chaudhary, S; Yadav, P; Parmanik, R and Singh, M (2019). The therapeutic and preventive efficacy of curcumin and its derivatives in esophageal cancer. Asian Pac. J. Cancer Prev., 20: 1329-1337.
Levine, CB; Bayle, J; Biourge, V and Wakshlag, JJ (2016). Effects and synergy of feed ingredients on canine neoplastic cell proliferation. BMC Vet. Res., 12: 159.
MacEwen, EG (1990). Spontaneous tumors in dogs and cats: Models for the study of cancer biology and treatment. Cancer Metastasis Rev., 9: 125-136.
Maheshwari, RK; Singh, AK; Gaddipati, J and Srimal, RC (2006). Multiple biological activities of curcumin: a short review. Life Sci., 78: 2081-2087.
Matos, AJ; Baptista, CS; Gärtner, MF and Rutteman, GR (2012). Prognostic studies of canine and feline mammary tumours: the need for standardized procedures. Vet. J., 193: 24-31.
Mills, SW; Musil, KM; Davies, JL; Hendrick, S; Duncan, C; Jackson, ML; Kidney, B; Philibert, H; Wobeser, BK and Simko, E (2015). Prognostic value of histologic grading for feline mammary carcinoma: a retrospective survival analysis. Vet. Pathol., 52: 238-249.
Moulton, JE (1990). Tumors in domestic animals. 5th Edn., Berkeley, University of California Press. PP: 722-765.
Overley, B; Shofer, FS; Goldschmidt, MH; Sherer, D and Sorenmo, KU (2005). Association between ovario-hysterectomy and feline mammary carcinoma. J. Vet. Intern. Med., 19: 560-563.
Preziosi, R; Sarli, G; Benazzi, C and Marcato, PS (1995). Detection of proliferating cell nuclear antigen (PCNA) in canine and feline mammary tumours. J. Comp. Pathol., 113: 301-313.
Rahmani, AH; Al Zohairy, MA; Aly, SM and Khan, MA (2014). Curcumin: a potential candidate in prevention of cancer via modulation of molecular pathways. Biomed. Res. Int., 2014: 761608.
Russo, J and Russo, IH (1998). Role of hormones in cancer initiation and progression. J. Mammary Gland Biol. Neoplasia. 3: 46-91.
Sethi, G and Tergaonkar, V (2009). Potential pharma-cological control of the NF-κB pathway. Trends Pharmacol. Sci., 30: 313-321.
Shanmugam, MK; Rane, G; Kanchi, MM; Arfuso, F; Chinnathambi, A; Zayed, ME; Alharbi, SA; Tan, BK; Kumar, AP and Sethi, G (2015). The multifaceted role of curcumin in cancer prevention and treatment. Molecules. 20: 2728-2769.
Shao, ZM; Shen, ZZ; Liu, CH; Sartippour, MR; Go, VL; Heber, D and Nguyen, M (2002). Curcumin exerts
multiple suppressive effects on human breast carcinoma cells. Int. J. Cancer. 98: 234-240.
Song, X; Zhang, M; Dai, E and Luo, Y (2019). Molecular targets of curcumin in breast cancer. Mol. Med. Rep., 19: 23-29.
Sorenmo, K (2003). Canine mammary gland tumors. Vet. Clin. North Am. Small Anim. Pract., 33: 573-596.
Tan, HK; Moad, AI and Tan, ML (2014). The mTOR signalling pathway in cancer and the potential mTOR inhibitory activities of natural phytochemicals. Asian Pac. J. Cancer Prev., 15: 6463-6475.
Tomeh, MA; Hadianamrei, R and Zhao, X (2019). A review of curcumin and its derivatives as anticancer agents. Int. J. Mol. Sci., 20: 1033.
Troselj, KG and Kujundzic, RN (2014). Curcumin in combined cancer therapy. Curr. Pharm. Des., 20: 6682-6696.
Wang, SC (2014). PCNA: a silent housekeeper or a potential therapeutic target? Trends Pharmacol. Sci., 35: 178-186.
Wang, Y; Yu, J; Cui, R; Lin, J and Ding, X (2016). Curcumin in treating breast cancer: a review. J. Lab. Autom., 21: 723-731.
Yim-im, W; Sawatdichaikul, O; Semsri, S; Horata, N; Mokmak, W; Tongsima, S; Suksamrarn, A and Choowongkomon, K (2014). Computational analyses of curcuminoid analogs against kinase domain of HER2. BMC Bioinform., 15: 261.
Zappulli, V; Rasotto, R; Caliari, D; Mainenti, M; Peña, L; Goldschmidt, MH and Kiupel, M (2015). Prognostic evaluation of feline mammary carcinomas: a review of the literature. Vet. Pathol., 52: 46-60.